4-Aminopyridine in the Treatment of Patients With Multiple Sclerosis: Long-term Efficacy and Safety

doi:10.1001/archneur.1994.00540150090022

You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.

Vol. 51 No. 3, March 1994

Online Only
	•	Online First Table of Contents

Original Contributions

•	Online Features

This Article
•	References
•	Full text PDF
•	Reply to article
•	Send to a friend
•	Save in My Folder
•	Save to citation manager
•	Permissions

Citing Articles
•	Citation map
•	Citing articles on HighWire
•	Citing articles on Web of Science (78)
•	Contact me when this article is cited

Related Content
•	Similar articles in this journal

Social Bookmarking
	What's this?

4-Aminopyridine in the Treatment of Patients With Multiple Sclerosis

Long-term Efficacy and Safety

Chris H. Polman, MD, PhD; Frits W. Bertelsmann, MD, PhD; Arie C. van Loenen, PharmD; Johan C. Koetsier, MD, PhD

Arch Neurol. 1994;51(3):292-296.

Abstract

Objective
To study the long-term efficacy and safety of 4-aminopyridinein patients with multiple sclerosis.

Design
Case series, follow-up varying from 6 to 32 months.

Setting
University referral center.

Patients
Thirty-one patients with definite MS, 23 of them being exposedto long-term administration (6 to 32 months) of 4-aminopyridine,since they showed a favorable initial response to the drug.

Interventions
Long-term oral treatment with 4-aminopyridine in daily dosesof up to 0.5 mg/kg of body weight.

Main Outcome Measures
Neurologic functions and symptoms as reported by the patients;side effects.

Results
Twenty of 23 patients who showed a favorable initial responsebenefited from long-term administration. Ambulation and fatigue(each in 13 patients) and visual function (in five patients)were most frequently reported to be improved. Three major sideeffects did occur during a follow-up of 406 patient months:a generalized epileptic seizure in two patients and hepatitisin one.

Conclusions
Although a substantial proportion of patients with multiplesclerosis seem to benefit from long-term administration of 4-aminopyridine,additional studies are needed to clarify the exact value ofthe drug.

Author Affiliations

From the Departments of Neurology (Drs Polman, Bertelsmann, and Koetsier) and Pharmacy (Dr van Loenen), Free University Hospital, Amsterdam, the Netherlands.

Add to CiteULike CiteULike Add to Connotea Connotea Add to Delicious Delicious Add to Digg Digg Facebook Add to Reddit Reddit Add to Technorati Technorati Twitter What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

HAGIL (Hamburg Vigil Study): a randomized placebo-controlled double-blind study with modafinil for treatment of fatigue in patients with multiple sclerosis
Moller et al.
Mult Scler 2011;17:1002-1009.
ABSTRACT | FULL TEXT

Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice.
de Sa et al.
Therapeutic Advances in Neurological Disorders 2011;4:139-168.
ABSTRACT

Treatment of walking impairment in multiple sclerosis with dalfampridine.
Blight
Therapeutic Advances in Neurological Disorders 2011;4:99-109.
ABSTRACT

Single-Dose Pharmacokinetics of Sustained-Release Fampridine (Fampridine-SR) in Healthy Volunteers and Adults With Renal Impairment
Smith et al.
J Clin Pharmacol 2010;50:151-159.
ABSTRACT | FULL TEXT

Aminopyridines Potentiate Synaptic and Neuromuscular Transmission by Targeting the Voltage-activated Calcium Channel {beta} Subunit
Wu et al.
J. Biol. Chem. 2009;284:36453-36461.
ABSTRACT | FULL TEXT

Dose comparison trial of sustained-release fampridine in multiple sclerosis
Goodman et al.
Neurology 2008;71:1134-1141.
ABSTRACT | FULL TEXT

Modafinil for fatigue in MS: A randomized placebo-controlled double-blind study
Stankoff et al.
Neurology 2005;64:1139-1143.
ABSTRACT | FULL TEXT

Transcranial magnetic stimulation as a provocation for epileptic seizures in multiple sclerosis
Haupts et al.
Mult Scler 2004;10:475-476.
ABSTRACT

Enhanced brain motor activity in patients with MS after a single dose of 3,4-diaminopyridine
Mainero et al.
Neurology 2004;62:2044-2050.
ABSTRACT | FULL TEXT

Pharmacokinetics of an Immediate-Release Oral Formulation of Fampridine (4-Aminopyridine) in Normal Subjects and Patients with Spinal Cord Injury
Hayes et al.
J Clin Pharmacol 2003;43:379-385.
ABSTRACT | FULL TEXT

Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine
Rossini et al.
Mult Scler 2001;7:354-358.
ABSTRACT

Selective Blocking of Voltage-Gated K+ Channels Improves Experimental Autoimmune Encephalomyelitis and Inhibits T Cell Activation
Beeton et al.
J. Immunol. 2001;166:936-944.
ABSTRACT | FULL TEXT

Modalities of fatigue in multiple sclerosis: correlation with clinical and biological factors
lriarte et al.
Mult Scler 2000;6:124-130.
ABSTRACT

Effects of 4-aminopyridine on demyelinated axons, synapses and muscle tension
Smith et al.
Brain 2000;123:171-184.
ABSTRACT | FULL TEXT

Investigational drug therapies for treatment of multiple sclerosis
Panitch
Mult Scler 1996;2:66-77.
ABSTRACT

4-Aminopyridine Is Superior to 3,4-Diaminopyridine in the Treatment of Patients With Multiple Sclerosis
Polman et al.
Arch Neurol 1994;51:1136-1139.
ABSTRACT

| | |